Figure 1 | British Journal of Cancer

Figure 1

From: Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features

Figure 1

Analysis of methylation status of RASSF1 and RASSF2 promoter CpG island. COBRA was carried out using bisulphite-treated DNA from colorectal adenomas and cancers. A representative result for tumour tissue samples with/without RASSF1 or RASSF2 promoter methylation is shown. A1 is a sample without RASSF1 and RASSF2 methylation. A2 and C2 are samples with RASSF2 methylation, and without RASSF1 methylation. C1 is a sample with RASSF1 methylation, and without RASSF2 methylation. A, adenoma samples; C, cancer samples; M, methylated alleles; HCT116, colon cancer cell line used as a negative control for RASSF1 and RASSF2 methylation; RKO, colon cancer cell line used as a positive control for RASSF1 and RASSF2 methylation; H2O, sample without DNA.

Back to article page